希罗达联合奥沙利铂在老年大肠癌患者术后化疗的临床应用

Xeloda plus Oxaliplatin Used in Chemotherapy after the Operation for Senile Colorectal Carcinoma

评价希罗达联合奥沙利铂方案（Xelox方案）在老年大肠癌患者术后化疗的疗效与毒副反应。31例老年大肠癌患者术后第5周均采用Xelox方案治疗，希罗达片1250mg／m^2，每日2次，第1-14d口服，休息7d；奥沙利铂注射剂130mg／m^2，第1天静脉滴注，维持2h。21d为1个疗程。结果显示，31例除1例均接受了6个疗程的化疗，随访1年，其中无复发或转移26例，复发或转移4例，死亡1例，总有效率83．8％。治疗过程中，主要毒副反应有厌食恶心（39％）、手足综合征（48％）、皮肤色素沉着（65％）等，但症状较轻，均可耐受，只有16％的患者出现I度骨髓抑制。结果表明，Xelox方案用药方便，疗效肯定，副作用低，特别适用于对其他化疗药物耐受性较差的老年患者。

The objective of this study was to evaluate the therapeutic affects and adverse reaction of Xelox protocols used in postoperational chemotherapy for senile colorectal cancer. At 5th week after operation the 31 senile patients with colorectal cancer were treated with xelox protocols ： tablet of xeloda, 1250mg/m^2,2 times/day, on l st-14th day, orally administered; to stop medication for 7 days, then the injection of Oxali plation was injected i. v（on the 1st to maintain drug for 2 hours） ;one treatment course was 21 days, As resuits,except for one patient rest patients were all treated up to 6 treatment course; Follow-up of one year showed that 26 patients had not recurrence and metastasis, 4 patients suffered from recurrence and metastasis,one died,thus total effective rate was 83.8%; their main adverse reactions were anorexin and nausea （39%）, hand-foot syndrome （48%）, skin pigmentation （ 65%）, etc, but their symptoms were all milder, the patients can tolerate them,only 16% of patients suffered from I grade bone marrow suppression. Above-mentioned results show that Xelox protocols has the advantages such as easily administering,certain curative effects and milder adverse reaction,especially be suitable for the senile patients who have poor toler ance to other chemotherapeutic drugs.